These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 25912081)

  • 41. Differentiation but not ALS mutations in FUS rewires motor neuron metabolism.
    Vandoorne T; Veys K; Guo W; Sicart A; Vints K; Swijsen A; Moisse M; Eelen G; Gounko NV; Fumagalli L; Fazal R; Germeys C; Quaegebeur A; Fendt SM; Carmeliet P; Verfaillie C; Van Damme P; Ghesquière B; De Bock K; Van Den Bosch L
    Nat Commun; 2019 Sep; 10(1):4147. PubMed ID: 31515480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules.
    Vance C; Scotter EL; Nishimura AL; Troakes C; Mitchell JC; Kathe C; Urwin H; Manser C; Miller CC; Hortobágyi T; Dragunow M; Rogelj B; Shaw CE
    Hum Mol Genet; 2013 Jul; 22(13):2676-88. PubMed ID: 23474818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells.
    Sun X; Song J; Huang H; Chen H; Qian K
    Stem Cell Res Ther; 2018 Nov; 9(1):315. PubMed ID: 30442180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation of an induced pluripotent stem cell line (UCSCi001-A) from a patient with early-onset amyotrophic lateral sclerosis carrying a FUS variant.
    Martello F; Lattante S; Doronzio PN; Conte A; Bisogni G; Orteschi D; Pirozzi F; Sabatelli M; Zollino M; Marangi G
    Stem Cell Res; 2021 Aug; 55():102461. PubMed ID: 34303285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of hub molecules of FUS-ALS by Bayesian gene regulatory network analysis of iPSC model: iBRN.
    Nogami M; Ishikawa M; Doi A; Sano O; Sone T; Akiyama T; Aoki M; Nakanishi A; Ogi K; Yano M; Okano H
    Neurobiol Dis; 2021 Jul; 155():105364. PubMed ID: 33857636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug screening for ALS using patient-specific induced pluripotent stem cells.
    Egawa N; Kitaoka S; Tsukita K; Naitoh M; Takahashi K; Yamamoto T; Adachi F; Kondo T; Okita K; Asaka I; Aoi T; Watanabe A; Yamada Y; Morizane A; Takahashi J; Ayaki T; Ito H; Yoshikawa K; Yamawaki S; Suzuki S; Watanabe D; Hioki H; Kaneko T; Makioka K; Okamoto K; Takuma H; Tamaoka A; Hasegawa K; Nonaka T; Hasegawa M; Kawata A; Yoshida M; Nakahata T; Takahashi R; Marchetto MC; Gage FH; Yamanaka S; Inoue H
    Sci Transl Med; 2012 Aug; 4(145):145ra104. PubMed ID: 22855461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of a human induced pluripotent stem cell line (SMUSHi002-A) from an ALS patient carrying a heterozygous mutation c.1562G > A in the FUS gene.
    Tang M; Xiong M; Zhou W; Lei J; Huang M; Huang C; Wang F; Liu J; Li J; Xu X
    Stem Cell Res; 2024 Feb; 74():103286. PubMed ID: 38141357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS.
    Arenas A; Chen J; Kuang L; Barnett KR; Kasarskis EJ; Gal J; Zhu H
    Hum Mol Genet; 2020 Sep; 29(16):2684-2697. PubMed ID: 32691043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11.
    Hedges EC; Topp S; Shaw CE; Nishimura AL
    Stem Cell Res; 2021 Apr; 52():102246. PubMed ID: 33610019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene.
    Kent L; Vizard TN; Smith BN; Topp SD; Vance C; Gkazi A; Miller J; Shaw CE; Talbot K
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):557-62. PubMed ID: 24899262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis.
    De Santis R; Santini L; Colantoni A; Peruzzi G; de Turris V; Alfano V; Bozzoni I; Rosa A
    Stem Cell Reports; 2017 Nov; 9(5):1450-1462. PubMed ID: 28988989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons.
    Shum C; Hedges EC; Allison J; Lee YB; Arias N; Cocks G; Chandran S; Ruepp MD; Shaw CE; Nishimura AL
    Stem Cell Reports; 2024 Feb; 19(2):187-195. PubMed ID: 38242131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that Is Rescued by Drugs Inducing Autophagy.
    Marrone L; Poser I; Casci I; Japtok J; Reinhardt P; Janosch A; Andree C; Lee HO; Moebius C; Koerner E; Reinhardt L; Cicardi ME; Hackmann K; Klink B; Poletti A; Alberti S; Bickle M; Hermann A; Pandey UB; Hyman AA; Sterneckert JL
    Stem Cell Reports; 2018 Feb; 10(2):375-389. PubMed ID: 29358088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutant FUS and ELAVL4 (HuD) Aberrant Crosstalk in Amyotrophic Lateral Sclerosis.
    De Santis R; Alfano V; de Turris V; Colantoni A; Santini L; Garone MG; Antonacci G; Peruzzi G; Sudria-Lopez E; Wyler E; Anink JJ; Aronica E; Landthaler M; Pasterkamp RJ; Bozzoni I; Rosa A
    Cell Rep; 2019 Jun; 27(13):3818-3831.e5. PubMed ID: 31242416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [ALS disease modeling and drug screening using patient-specific iPS cells].
    Egawa N; Inoue H
    Rinsho Shinkeigaku; 2013; 53(11):1020-2. PubMed ID: 24291866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aggregation of FET Proteins as a Pathological Change in Amyotrophic Lateral Sclerosis.
    Furukawa Y; Tokuda E
    Adv Exp Med Biol; 2017; 925():1-12. PubMed ID: 27311318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Amyotrophic lateral sclerosis (ALS) with the mutations in the fused in sarcoma/translocated in liposarcoma gene].
    Aoki M
    Rinsho Shinkeigaku; 2013; 53(11):1080-3. PubMed ID: 24291885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
    Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
    Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation.
    Sama RR; Fallini C; Gatto R; McKeon JE; Song Y; Rotunno MS; Penaranda S; Abdurakhmanov I; Landers JE; Morfini G; Brady ST; Bosco DA
    Sci Rep; 2017 Mar; 7(1):115. PubMed ID: 28273913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic Lateral Sclerosis.
    Shelkovnikova TA; An H; Skelt L; Tregoning JS; Humphreys IR; Buchman VL
    Cell Rep; 2019 Dec; 29(13):4496-4508.e4. PubMed ID: 31875556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.